{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:21Z","timestamp":1740144141865,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007344","name":"Achmea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007344","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"DOI":"10.1007\/s40263-021-00802-3","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:02:45Z","timestamp":1618038165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-5767","authenticated-orcid":false,"given":"Arnold P. M.","family":"van der Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"\u00d6nsesveren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 I.","family":"Wierdsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roos","family":"van Westrhenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aartjan T. F.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels C. L.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,10]]},"reference":[{"key":"802_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2147\/NDT.S37485","volume":"9","author":"WT Chien","year":"2013","unstructured":"Chien WT, Yip AL. Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. Neuropsychiatr Dis Treat. 2013;9:1311\u201332.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"1","key":"802_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79\u2013104.","journal-title":"Mol Psychiatry."},{"issue":"3","key":"802_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.psc.2007.04.002","volume":"30","author":"MJ Byerly","year":"2007","unstructured":"Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin N Am. 2007;30(3):437\u201352.","journal-title":"Psychiatr Clin N Am."},{"issue":"10","key":"802_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"802_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/schbul\/sbj075","volume":"32","author":"DI Velligan","year":"2006","unstructured":"Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724\u201342.","journal-title":"Schizophr Bull."},{"issue":"1","key":"802_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JCP.0000000000000623","volume":"37","author":"HY Chan","year":"2017","unstructured":"Chan HY, Pan YJ, Chen JJ, Chen CH. Time to discontinuation of second-generation antipsychotics versus haloperidol and sulpiride in people with schizophrenia: a naturalistic, comparative study. J Clin Psychopharmacol. 2017;37(1):13\u201320.","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"802_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","volume":"2","author":"FJ Acosta","year":"2012","unstructured":"Acosta FJ, Hernandez JL, Pereira J, Herrera J, Rodriguez CJ. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74\u201382.","journal-title":"World J Psychiatry."},{"issue":"10 Suppl 17","key":"802_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1092852900026304","volume":"12","author":"JM Kane","year":"2007","unstructured":"Kane JM. Treatment adherence and long-term outcomes. CNS Spectr. 2007;12(10 Suppl 17):21\u20136.","journal-title":"CNS Spectr."},{"issue":"2","key":"802_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334.","journal-title":"J Med Econ."},{"issue":"5789","key":"802_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/bmj.4.5789.710","volume":"4","author":"HM van Praag","year":"1971","unstructured":"van Praag HM, Schut T, Dols L, van Schilfgaarden R. Controlled trial of penfluridol in acute psychosis. Br Med J. 1971;4(5789):710\u20133.","journal-title":"Br Med J."},{"key":"802_CR11","doi-asserted-by":"crossref","unstructured":"Soares BG, Lima MS. Penfluridol for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD002923.","DOI":"10.1002\/14651858.CD002923.pub2"},{"issue":"3","key":"802_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1176\/ps.2008.59.3.315","volume":"59","author":"B Zhu","year":"2008","unstructured":"Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008;59(3):315\u20137.","journal-title":"Psychiatr Serv."},{"issue":"1\u20133","key":"802_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2011.04.028","volume":"131","author":"J Kreyenbuhl","year":"2011","unstructured":"Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res. 2011;131(1\u20133):127\u201332.","journal-title":"Schizophr Res."},{"issue":"12","key":"802_CR14","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med."},{"key":"802_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-244X-6-8","volume":"6","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.","journal-title":"BMC Psychiatry"},{"issue":"9","key":"802_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.1742-1241.2011.02743.x","volume":"65","author":"AJ Brnabic","year":"2011","unstructured":"Brnabic AJ, Kelin K, Ascher-Svanum H, Montgomery W, Kadziola Z, Karagianis J. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. Int J Clin Pract. 2011;65(9):945\u201353.","journal-title":"Int J Clin Pract."},{"issue":"1","key":"802_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eurpsy.2005.12.001","volume":"21","author":"JM Haro","year":"2006","unstructured":"Haro JM, Novick D, Belger M, Jones PB. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry. 2006;21(1):41\u20137.","journal-title":"Eur Psychiatry."},{"issue":"6","key":"802_CR18","doi-asserted-by":"publisher","first-page":"e0179049","DOI":"10.1371\/journal.pone.0179049","volume":"12","author":"F Decuypere","year":"2017","unstructured":"Decuypere F, Sermon J, Geerts P, Denee TR, De Vos C, Malfait B, et al. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: a retrospective database study. PLoS ONE. 2017;12(6):e0179049.","journal-title":"PLoS ONE"},{"key":"802_CR19","unstructured":"STROBE guidelines. https:\/\/www.strobe-statement.org\/."},{"key":"802_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/PPA.S11934","volume":"4","author":"K Kelin","year":"2010","unstructured":"Kelin K, Brnabic AJ, Newton R, Escamilla RI, Chuo LJ, Simu M, et al. Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence. 2010;4:301\u201311.","journal-title":"Patient Prefer Adherence."},{"issue":"4","key":"802_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1176\/ps.2007.58.4.482","volume":"58","author":"L Shi","year":"2007","unstructured":"Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4):482\u20138.","journal-title":"Psychiatr Serv."},{"issue":"2","key":"802_CR22","first-page":"113","volume":"23","author":"E Zur","year":"2019","unstructured":"Zur E. Penfluridol, a unique psychiatric medicine for the treatment of chronic schizophrenia. Int J Pharm Compd. 2019;23(2):113\u20139.","journal-title":"Int J Pharm Compd."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00802-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00802-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00802-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T18:02:23Z","timestamp":1622656943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00802-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,10]]},"references-count":22,"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00802-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2021,4,10]]},"assertion":[{"value":"6 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access was funded by Amsterdam UMC (Vrije Universiteit Amsterdam). Zilveren Kruis Achmea supported the study in the form of salaries for Arnold van der Lee, as well as with data. Zilveren Kruis Achmea had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arnold P.M. van der Lee, Ibrahim \u00d6nsesveren, Andr\u00e9 I. Wierdsma, Roos van Westrhenen, Aartjan T.F. Beekman, Lieuwe de Haan, and Niels C.L. Mulder declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As the data in the study database could not be linked to individual patients, no informed consent or permission from a Medical Ethics Committee were necessary under Dutch and European laws.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The registry data that were used in this study are not publicly available due to Dutch privacy laws and regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"APMvdL, IO, AIW, LdH and NCLM conceived and designed the study. APMvdL and IO collected and analyzed the data, and wrote the initial manuscript. AIW provided support during the data analysis phase. APMvdL, IO, AIW, RvW, ATFB, LdH and NCLM interpreted the results and revised the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of this work<b>.<\/b>","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}